FDA Corrects Typo in Cancer Drug Approval Withdrawal Notice
Published Date: 10/3/2025
Notice
Summary
The FDA fixed a mistake in their August 4, 2025, announcement about pulling approval for 39 drug applications. They accidentally listed the wrong drug number for Zinecard, a cancer treatment medicine, and now corrected it. This change affects drug makers and users by making sure the right drug info is clear before the September 3, 2025 deadline.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Approval Withdrawals for 39 NDAs
The FDA announced the withdrawal of approval for 39 new drug applications (NDAs), with the withdrawals effective September 3, 2025. If you use any medicine covered by those 39 NDAs, the approvals for those products are listed as withdrawn as of that date.
Correction of Zinecard NDA Number
The FDA corrected an error in its August 4, 2025 notice: the correct NDA number for Zinecard (dexrazoxane HCl) Injectable is NDA 020212 (not NDA 021290). The correction lists Zinecard in EQ 250 mg base/vial and EQ 500 mg base/vial and clarifies the record before the September 3, 2025 withdrawal date.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16959, Frequently Asked Questions-Developing Potential Cellular and Gene Therapy Products; Final Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance titled "Frequently asked Questions--Developing Potential Cellular and Gene Therapy Products." The guidance document provides industry with answers to frequently asked questions (FAQs) and commonly faced issues that arise during the development of cellular and gene therapy (CGT) products. The FAQs represent common questions directed to the Agency and span multiple disciplines, including regulatory review; chemistry, manufacturing, and controls (CMC); pharmacology/toxicology; clinical; and clinical pharmacology. This guidance announced in this notice finalizes the draft guidance of the same title issued on November 19, 2024.
2026-16939, GNT USA, LLC.; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by GNT USA, LLC., c/o Exponent, Inc., proposing that we amend our color additive regulations to provide for the safe use of safflower (Carthamus tinctorius L.) extract as a color additive in various foods at levels consistent with good manufacturing practices.
2026-16942, Food Additives Permitted in Feed and Drinking Water of Animals; Chromium DL-methionine Chelate
The Food and Drug Administration (FDA, we, or the Agency) is amending the regulations for food additives permitted in feed and drinking water of animals to provide for the safe use of chromium DL- methionine chelate as a nutritional source of chromium in cattle feed. This action is in response to a food additive petition filed by Zinpro Corp.
Previous / Next Documents
Previous: 2025-19436, URAL Airlines JSC, Utrenniy Lane 1-g, Yekaterinburg, Russia 620025; Order Renewing Temporary Denial of Export Privileges
URAL Airlines from Russia is still banned from exporting certain goods because they’ve repeatedly broken the rules. This export ban, first started in 2022, has been renewed again to keep things safe and legal. The ban means URAL can’t do business with U.S. exports for now, and this will continue until further notice.
Next: 2025-19441, Astronomy and Astrophysics Advisory Committee; Notice of Meeting
The Astronomy and Astrophysics Advisory Committee is meeting virtually on November 7, 2025, to hear updates from NASA, NSF, DOE, and others about space science projects. They’ll talk about teamwork between agencies and plan recommendations to boost future space research. Anyone interested can join online, and the committee’s report is due by March 15, 2026.